IGF2 and esophageal cancer: The loss of IGF2 imprinting or dysregulation of its expression through other mechanisms have been associated with increased chemoresistance, radiotherapy resistance, and immune evasion in diverse cancer models in vitro and in vivo; however, IGF2 imprinting was also associated with improved disease-free survival of esophageal cancer patients [53, 58–60].